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Outcome of patients with colorectal cancer (CRC) is highly depen-
dent on the essential and additional prognostic factors from the TNM
staging system proposed by the UICC and AJCC. Additionally, novel
and promising prognostic biomarkers are listed in the WHO classifi-
cation 2019. At the invasive front of CRC, there are two such factors
within the tumour microenvironment (TME) which battle for prog-
nosis: tumour budding [1] and the immune cell infiltration [2].
Tumour budding defined as single cells or clusters up to four
tumour cells is found at the invasion front of CRC [1]. It is associated
with local and distant metastases and is therefore a histomorphologi-
cal biomarker of tumour progression and worse prognosis [1].
According to the International Tumour Budding Consensus Confer-
ence (ITBCC) 2016, tumour budding is graded based on bud number
into BD1 (04 buds/hotspot 0.785mm2), BD2 (59 buds/hotspot
0.785mm2) and BD3 (10 buds/hotspot 0.785 mm2), and may poten-
tially support patient management in three clinical scenarios: first, in
pT1 CRC, high grade tumour budding is associated with presence of
local lymph node metastases and is therefore an indicator for a radi-
cal oncologic resection [3]; second, in stage II CRC, high grade tumour
budding is an independent prognostic factor and may select stage II
CRC patients for adjuvant treatment [4]; third, intratumoural budding
(ITB) defined as tumour buds within the main tumour body can be
assessed in preoperative biopsies and be a potential indicator for
neo-adjuvant therapy [5].
In allegory to history, tumour buds can be seen as the heavy cav-
alry of CRC, but they need the ideal battleground. In the case of the
invasive cancer front, this ideal battleground corresponds to a
tumour microenvironment with a pronounced desmoplastic stroma
reaction. Not surprisingly, tumour budding is highly associated with
the mesenchymal Consensus Molecular Subtype (CMS) 4 [6]. The
dynamic of tumour buds is dependent on the interaction with other
cell types of the TME such as stromal and inflammatory cells [7].DOI of original article: http://dx.doi.org/10.1016/j.ebiom.2020.102860.
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transition (EMT) and their immunohistochemical profile clearly dif-
fers from the neoplastic cell population of the main tumour body [7].
Often found in tumour buds are overexpression of EpCam, nuclear
b-catenin, CXCL12, TrkB, Pontin, CK7, NFkB, Laminin5, CathepsinB, L1
and MMP9, whereas membraneous E-Cadherin, Ki-67, RKIP, Cdx2,
MUC2 and Caspase3 are under-expressed or lost [7]. This profile
reflects the involvement of tumour budding in lymphovascular inva-
sion and further development of local and distant metastases.
Now the question arises: what opposes the heavy cavalry at the
invasive front of CRC? Already in 1986, Jass proposed lymphocytic infil-
tration as a prognostic factor in rectal cancer [8]. In the last two deca-
des, the role of the immune infiltration was systematically investigated
and implemented as the Immunoscore [2]. The Immunoscore was
recently validated by an international consortium supported by the
Society for Immunotherapy of Cancer (SITC) for its clinical use as a
strong prognostic factor in stage I-III colon cancer patients. The consen-
sus immunoscore includes the intratumoral and peritumoral density of
CD3+ and CD8+ T-cell effectors using a digital image analysis approach,
which is intended to help increase the reproducibility of the immuno-
score and its promising and selective role for immunotherapy [2].
Nevertheless, patient outcome in CRC is strongly influenced by the
result at the end of the battle between tumour-related and host-
related factors. A combined scoring system including tumour budding
and immune cells is therefore a very promising approach to better
assess prognosis, especially if its evaluation and validation is based on
automated digital methods. Indeed, several studies have shown a com-
bined tumour buds-lymphocyte index to be a more accurate prognos-
tic factor than tumour budding or immune cells alone [9].
In this research article of EBioMedicine, Fujiyoshi et al. provided new
evidence supporting this “attacker-defender” model based on tumour
budding and adaptive anti-tumour immunity using multiplex immuno-
fluorescence, machine learning algorithms and image analysis [10]. The
study’s strength is based on large and molecularly well characterized
cohorts and a digital pathology approach highlighting two important
aspects: first, the density of CD3+CD8+ and CD3+CD8+CD45+ was
inversely associated with tumour budding count which underlines the
role for cytotoxic anti-tumour immunity in suppressing microinvasion
and second, the prognostic value of tumour budding based on the ITBCC
proposal, independent of molecular and immune parameters.
Tumour budding represents an aggressive morphologic feature at
the invasive tumour front and is responsible for adverse outcome in all
stages of CRC. Hypothesis-driven research into an anti-budding ther-
apy would be a novel and important avenue for further investigation.der the CC BY-NC-ND license. (http://creativecommons.org/licenses/by-nc-nd/4.0/)
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